Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Raghad S. Alsulami has a total of 3 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Co-dynamics of influenza and COVID-19 with CTL immunity

    by Aeshah A. Raezah, A. M. Elaiw, R. S. Alsulami

    Influenza and COVID-19 are two respiratory diseases that cause significant illness and death. Influenza A virus (IAV) is more effective at causing disease compared to types B, C, and D. The novel SARS-CoV-2, or severe acute respiratory syndrome coronavirus 2, is the cause of COVID-19. These two viruses have similar seasonal patterns, symptoms, transmission methods, and immune responses. Several studies have reported many individuals with concurrent infections with both IAV and SARS-CoV-2. Recent works have looked into modeling the co-dynamics of SARS-CoV-2 and IAV, but have not taken cytotoxic T lymphocyte (CTL) immunity into account. This paper investigates the global co-dynamics of IAV and SARS-CoV-2 in vivo, focusing on the role of CTL in killing virus-infected cells during dual infection. Three types of distributed-time delays are included in the suggested model: delay in the emergence of latently infected cells, delay in the activation of latent infected cells, and delay in the maturation of freshly created virions. The model is examined qualitatively, its steady states are computed, and the stability of the steady states is established by using the Lyapunov method, and the outcomes are illustrated through simulations. The impact of CTL immunity on the IAV and SARS-CoV-2 dual infection is discussed. Our results imply that while CTL immunity is essential for preventing SARS-CoV-2 and IAV dual infection, it may also allow both viruses to coexist in specific situations. Additionally, the study discusses how time delays influence the dynamics of dual infection, noting that extended delays can have effects similar to those of antiviral treatments. A long enough delay causes the virus to evolve more slowly, controlling and eventually eliminating the dual infection. This provides us with some recommendations for novel medications that could extend the duration of latent infection, reactivation, or maturation of newly generated virions. Various clinical phenomena, including viral clearance, viral interference, and coexistence of two types of viruses, can be observed using our proposed model.


  • Open Access

    Dynamic Behaviors of a COVID-19 and Influenza Co-Infection Model with Time Delays and Humoral Immunity

    by Ahmed M. Elaiw, Raghad S. Alsulami, Aatef D. Hobiny

    Co-infections with respiratory viruses were reported in hospitalized patients in several cases. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A virus (IAV) are two respiratory viruses and are similar in terms of their seasonal occurrence, clinical manifestations, transmission routes, and related immune responses. SARS-CoV-2 is the cause of coronavirus disease 2019 (COVID-19). In this paper, we study the dynamic behaviors of an influenza and COVID-19 co-infection model in vivo. The role of humoral (antibody) immunity in controlling the co-infection is modeled. The model considers the interactions among uninfected epithelial cells (ECs), SARS-CoV-2-infected ECs, IAV-infected ECs, SARS-CoV-2 particles, IAV particles, SARS-CoV-2 antibodies, and IAV antibodies. The model is given by a system of delayed ordinary differential equations (DODEs), which include four time delays: (i) a delay in the SARS-CoV-2 infection of ECs, (ii) a delay in the IAV infection of ECs, (iii) a maturation delay of newly released SARS-CoV-2 virions, and (iv) a maturation delay of newly released IAV virions. We establish the non-negativity and boundedness of the solutions. We examine the existence and stability of all equilibria. The Lyapunov method is used to prove the global stability of all equilibria. The theoretical results are supported by performing numerical simulations. We discuss the effects of antiviral drugs and time delays on the dynamics of influenza and COVID-19 co-infection. It is noted that increasing the delay length has a similar influence to that of antiviral therapies in eradicating co-infection from the body.


  • Open Access

    Modeling and Stability Analysis of Within-Host IAV/SARS-CoV-2 Coinfection with Antibody Immunity

    by Ahmed M. Elaiw, Raghad S. Alsulami, Aatef D. Hobiny

    Studies have reported several cases with respiratory viruses coinfection in hospitalized patients. Influenza A virus (IAV) mimics the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) with respect to seasonal occurrence, transmission routes, clinical manifestations and related immune responses. The present paper aimed to develop and investigate a mathematical model to study the dynamics of IAV/SARS-CoV-2 coinfection within the host. The influence of SARS-CoV-2-specific and IAV-specific antibody immunities is incorporated. The model simulates the interaction between seven compartments, uninfected epithelial cells, SARS-CoV-2-infected cells, IAV-infected cells, free SARS-CoV-2 particles, free IAV particles, SARS-CoV-2-specific antibodies and IAV-specific antibodies. The regrowth and death of the uninfected epithelial cells are considered. We study the basic qualitative properties of the model, calculate all equilibria and investigate the global stability of all equilibria. The global stability of equilibria is established using the Lyapunov method. We perform numerical simulations and demonstrate that they are in good agreement with the theoretical results. The importance of including the antibody immunity into the coinfection dynamics model is discussed. We have found that without modeling the antibody immunity, the case of IAV and SARS-CoV-2 coexistence is not observed. Finally, we discuss the influence of IAV infection on the dynamics of SARS-CoV-2 single-infection and vice versa.


  • Open Access

    Global dynamics of IAV/SARS-CoV-2 coinfection model with eclipse phase and antibody immunity

    by A. M. Elaiw, Raghad S. Alsulami, A. D. Hobiny

    Coronavirus disease 2019 (COVID-19) and influenza are two respiratory infectious diseases of high importance widely studied around the world. COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while influenza is caused by one of the influenza viruses, A, B, C, and D. Influenza A virus (IAV) can infect a wide range of species. Studies have reported several cases of respiratory virus coinfection in hospitalized patients. IAV mimics the SARS-CoV-2 with respect to the seasonal occurrence, transmission routes, clinical manifestations and related immune responses. The present paper aimed to develop and investigate a mathematical model to study the within-host dynamics of IAV/SARS-CoV-2 coinfection with the eclipse (or latent) phase. The eclipse phase is the period of time that elapses between the viral entry into the target cell and the release of virions produced by that newly infected cell. The role of the immune system in controlling and clearing the coinfection is modeled. The model simulates the interaction between nine compartments, uninfected epithelial cells, latent/active SARS-CoV-2-infected cells, latent/active IAV-infected cells, free SARS-CoV-2 particles, free IAV particles, SARS-CoV-2-specific antibodies and IAV-specific antibodies. The regrowth and death of the uninfected epithelial cells are considered. We study the basic qualitative properties of the model, calculate all equilibria, and prove the global stability of all equilibria. The global stability of equilibria is established using the Lyapunov method. The theoretical findings are demonstrated via numerical simulations. The importance of considering the antibody immunity in the coinfection dynamics model is discussed. It is found that without modeling the antibody immunity, the case of IAV and SARS-CoV-2 coexistence will not occur. Further, we discuss the effect of IAV infection on the dynamics of SARS-CoV-2 single infection and vice versa.